Senores Pharmaceuticals Complete Financial Statements
In FY2026, Senores Pharmaceuticals (SENORES) reported revenue ₹193 Cr, net profit ₹37 Cr and EPS ₹7.96, with a net profit margin of 19.2% and ROE of 4.0%. Full financial statements from FY2022 to FY2026 (5 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Examine SENORES earnings for recent quarterly revenue, profit and EPS trends.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
SENORES Revenue, Net Profit & EBITDA — Year-on-Year Growth
SENORES YoY (Mar 2025 vs Mar 2026) — revenue +53.2%, net profit +105.6%, EBITDA +109.7%, expenses +34.7%. Analyse SENORES shareholding pattern to track promoter, FII and institutional holdings.
SENORES Income Statement — Revenue, EBITDA & Net Profit
Senores Pharmaceuticals revenue ₹193 Cr, EBITDA ₹65 Cr, net profit ₹37 Cr, EPS ₹7.96 (2026) — net profit margin 19.2%. For live price, earnings ratios and company overview, see Senores Pharmaceuticals stock price NSE.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 193 | 159 | 126 | 134 | 178 | 100 | 104 | 80 | 108 | 80 |
| Expenses | 128 | 112 | 95 | 104 | 121 | 77 | 80 | 59 | 77 | 64 |
| EBITDA | 65 | 47 | 31 | 30 | 58 | 23 | 24 | 21 | 31 | 16 |
| Operating Profit Margin % | 27.00% | 27.00% | 17.00% | 20.00% | 29.00% | 21.00% | 22.00% | 26.00% | 25.00% | 19.00% |
| Depreciation | 9 | 8 | 5 | 6 | 8 | 4 | 4 | 4 | 4 | 3 |
| Interest | 9 | 6 | 5 | 5 | 5 | 5 | 3 | 5 | 6 | 3 |
| Profit Before Tax | 47 | 41 | 21 | 27 | 45 | 16 | 18 | 14 | 21 | 10 |
| Tax | 11 | 11 | 3 | 5 | 11 | 3 | 3 | 3 | 4 | 3 |
| Net Profit | 37 | 30 | 18 | 21 | 34 | 13 | 14 | 11 | 16 | 7 |
| Earnings Per Share (₹) | 7.96 | 6.54 | 3.81 | 4.60 | 7.29 | 3.92 | 8.03 | 3.39 | 5.04 | 4.01 |
SENORES Balance Sheet — Assets, Liabilities & Shareholders' Equity
SENORES total assets ₹1,604 Cr, total equity ₹934 Cr, total liabilities ₹ Cr (2026) — ROE 4.0%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| ASSETS | |||||
| Total Assets | 1,604 | 1,227 | 622 | 131 | 59 |
| Current Assets | 812 | 722 | 251 | 51 | 27 |
| Fixed Assets | 726 | 301 | 235 | 27 | 7 |
| Capital Work in Progress | 18 | 173 | 97 | 35 | 8 |
| Investments | 89 | 0 | 0 | 17 | 15 |
| Other Assets | 0 | 754 | 289 | 53 | 29 |
| LIABILITIES | |||||
| Total Liabilities | |||||
| Current Liabilities | 215 | 174 | 143 | 34 | 13 |
| Non-Current Liabilities | |||||
| SHAREHOLDERS' EQUITY | |||||
| Total Equity | 934 | 812 | 232 | 46 | 37 |
| Share Capital | 46 | 46 | 31 | 10 | 9 |
| Reserves & Surplus | 888 | 740 | 174 | 36 | 28 |
SENORES Cash Flow Statement — Operating, Investing & Financing
Senores Pharmaceuticals operating cash flow ₹-46 Cr, investing ₹-430 Cr, financing ₹573 Cr, net cash flow ₹98 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 |
|---|---|---|---|---|
| Operating Activities | -46 | -26 | -1 | -10 |
| Investing Activities | -430 | -54 | -48 | -24 |
| Financing Activities | 573 | 87 | 46 | 37 |
| Net Cash Flow | 98 | 8 | -3 | 2 |